{"links":{"html":"https://www.erudio.com/reports/cosinr-nct03223155","json":"https://www.erudio.com/reports/cosinr-nct03223155.json","markdown":"https://www.erudio.com/reports/cosinr-nct03223155.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"cosinr-03223155"}},"request":"https://www.erudio.com/contact?report=cosinr-03223155"},"offer":{"cited_commentary_sources":21,"verified_hcp_statements":235,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":37,"optional":true,"price_per_verified_person_usd":15,"price_usd":555,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"cosinr-nct03223155"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=cosinr-03223155","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/cosinr-nct03223155","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-30T18:11:23.657159Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the sample findings; the report description."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":1},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Number of serious adverse events"},{"claim_count":6,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":6,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":14,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":8,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":6,"title":"Safety and tolerability"},{"claim_count":22,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":13,"coverage":"discussed","id":"A1","source_count":7,"title":"Clinical enthusiasm, chemotherapy-free appeal and radiation's incremental value"},{"claim_count":23,"coverage":"discussed","id":"A2","source_count":6,"title":"Dose, target selection and continuity of systemic treatment"},{"claim_count":11,"coverage":"discussed","id":"A3","source_count":5,"title":"Human timing evidence, tissue biology and translational measurements"},{"claim_count":29,"coverage":"discussed","id":"A4","source_count":3,"title":"AREG, dormancy escape and the meaning of post-SBRT progression"},{"claim_count":56,"coverage":"discussed","id":"A5","source_count":1,"title":"Causal validation, failure-pattern analysis and clinical meaningfulness"},{"claim_count":22,"coverage":"discussed","id":"A6","source_count":5,"title":"Partial SBRT, treated-lesion control and complete consolidation"},{"claim_count":6,"coverage":"discussed","id":"A7","source_count":1,"title":"YTHDF2-associated dendritic-cell resistance and experimental targeting"},{"claim_count":31,"coverage":"discussed","id":"A8","source_count":2,"title":"Local-therapy analogues, scientific framing and patient counseling"}],"counts":{"cited_sources":23,"claims_by_expression_type":{"comparison":7,"experience":6,"interpretation":58,"opinion":81,"primary_context":2,"question":24,"restatement":25,"uncertainty":22,"unspecified":10},"claims_by_kind":{"protocol_statement":1,"publication_statement":3,"source_observation":231},"clinician_statements":181,"evidence_units":241,"findings":12,"organisational_accounts":2,"people_cited":39,"people_identity_verified":37,"people_total":41,"screened_sources":28,"verified_claims":235},"findings_index":[{"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":6},"has_counterview":true,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":7,"passages":9,"sources":4,"sources_by_kind":{"commentary":3,"registry":1}},"title":"Radiation's added systemic contribution remains an explicit question despite strong enthusiasm"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":6},"has_counterview":true,"limitations":3,"links":{"context":1,"support":10},"ma_question":true,"named_voices":5,"passages":8,"sources":7,"sources_by_kind":{"commentary":7}},"title":"Favorable concurrent-treatment reports use distinct endpoints and incomplete presentation summaries"},{"id":"F3","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":1,"questions":1,"restated":0,"views":6},"has_counterview":true,"limitations":5,"links":{"context":1,"support":9},"ma_question":true,"named_voices":5,"passages":8,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Avoiding systemic-treatment delay is a conditional argument, not an unconditional preference for concurrency"},{"id":"F4","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":5,"views":5},"has_counterview":true,"limitations":3,"links":{"context":1,"support":12},"ma_question":true,"named_voices":6,"passages":9,"sources":3,"sources_by_kind":{"commentary":2,"registry":1}},"title":"Misreading COSINR as oligometastatic consolidation changes the clinical question"},{"id":"F5","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":15},"has_counterview":true,"limitations":3,"links":{"context":0,"support":16},"ma_question":true,"named_voices":4,"passages":16,"sources":3,"sources_by_kind":{"commentary":3}},"title":"The AREG interpretation concerns possible dormancy escape, not a demonstrated increase in metastatic spread"},{"id":"F6","structure":{"claims":21,"claims_by_group":{"comparisons":0,"experience":0,"questions":7,"restated":2,"views":12},"has_counterview":true,"limitations":3,"links":{"context":0,"support":24},"ma_question":true,"named_voices":8,"passages":24,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Human validation, causal discrimination and real-world importance remain contested"},{"id":"F7","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":4,"views":6},"has_counterview":true,"limitations":4,"links":{"context":0,"support":14},"ma_question":true,"named_voices":3,"passages":11,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Partial-coverage concerns include a negative association and an explicit self-correction"},{"id":"F8","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":0,"views":5},"has_counterview":true,"limitations":3,"links":{"context":2,"support":8},"ma_question":true,"named_voices":5,"passages":8,"sources":3,"sources_by_kind":{"commentary":3}},"title":"More ablative radiation has a systemic-treatment trade-off, not just a local-control rationale"},{"id":"F9","structure":{"claims":15,"claims_by_group":{"comparisons":2,"experience":1,"questions":2,"restated":1,"views":9},"has_counterview":true,"limitations":3,"links":{"context":1,"support":15},"ma_question":true,"named_voices":7,"passages":16,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Evidence-generation concerns combine statistical power, accrual competition and disputed modality bias"},{"id":"F10","structure":{"claims":17,"claims_by_group":{"comparisons":0,"experience":0,"questions":6,"restated":2,"views":9},"has_counterview":true,"limitations":3,"links":{"context":0,"support":17},"ma_question":true,"named_voices":8,"passages":15,"sources":2,"sources_by_kind":{"commentary":2}},"title":"The rationale extends beyond abscopal effects, while timing and measurement remain unsettled"},{"id":"F11","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":5},"has_counterview":false,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":1,"passages":7,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"YTHDF2 adds a resistance hypothesis, not a clinically validated intervention or sequencing biomarker"},{"id":"F12","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":2,"views":11},"has_counterview":true,"limitations":4,"links":{"context":1,"support":17},"ma_question":true,"named_voices":10,"passages":15,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Patient-facing communication is a consequential controversy alongside the science"}],"medical_affairs_question":"What evidence would isolate SBRT's incremental benefit and validate actionable dose, timing or biomarker choices without overstating systemic harm?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Added benefit: enthusiasm does not resolve attribution"},{"id":"section-2","level":2,"title":"Concurrent-treatment reports: preserve the endpoint and occasion"},{"id":"section-3","level":2,"title":"Practical sequencing: what counts as waiting, and when does acceptable toxicity suffice?"},{"id":"section-4","level":2,"title":"Population framing: selected-lesion cytoreduction is not complete oligometastatic consolidation"},{"id":"section-5","level":2,"title":"AREG: possible residual-progression biology is not a net-harm conclusion"},{"id":"section-6","level":2,"title":"Clinical validation: the central disagreement is what would prove a meaningful human effect"},{"id":"section-7","level":2,"title":"Partial SBRT: technical questions, cohort clarification and retraction must travel together"},{"id":"section-8","level":2,"title":"Dose intensity: protect systemic therapy as well as local control"},{"id":"section-9","level":2,"title":"Building persuasive evidence: biological coherence versus feasible, definitive comparisons"},{"id":"section-10","level":2,"title":"Mechanistic rationale: beyond abscopal response, with unresolved measurements"},{"id":"section-11","level":2,"title":"YTHDF2: a correlative resistance signal with experimental therapeutic implications"},{"id":"section-12","level":2,"title":"Scientific framing, local-therapy analogues and patient counseling"},{"id":"section-13","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase1","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Number of serious adverse events"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F11","shared_claims":1},{"id":"F12","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F4","shared_claims":7},{"id":"F7","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":9}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":3},{"id":"F8","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F9","shared_claims":15}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-30T18:11:23.657159Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-30T22:21:39Z","record_hash":"115f4d688fa674440346c9a3ed8157785b12163c9bbe1919605b8c1ffccadf9e","release_hash":"bb6847f2c5df1439c53118ac716f766994a58469289db6d1759b1065d9f00425","report_id":"erudio-nct03223155","run_id":"2d3264a1-8d59-46ad-9884-643d7147e9bf","schema_version":"5.0","slug":"cosinr-03223155","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"COSINR examines the safety of giving stereotactic body radiotherapy concurrently or sequentially with nivolumab–ipilimumab in stage IV NSCLC. Commentary comes from X posts and threaded exchanges. Debate centers on whether radiation adds systemic benefit, when concurrent SBRT–immunotherapy is appropriate, and the contested clinical relevance of proposed dormancy escape. The sources place COSINR presentation findings at ASTRO 2020 and COSINR trial results at WCLC2023.","meta_description":"28 sources screened · 235 verified statements (181 from clinicians verified by NPI or staff page) from 23 sources · 12 findings. Updated Oct 30, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-6706bf996dc914d34523"],"id":"F1","paraphrase":"An X-thread post asks how radiation’s contribution in COSINR can be separated from a tumor’s responsiveness to immunotherapy.","source_channel":"x_thread","source_date":"2025-11-20","title":"Radiation's added systemic contribution remains an explicit question despite strong enthusiasm"},{"cited_claim_ids":["claim-2335c166a96e4c9daf6c","claim-f75a63931d795ee7ee3f","claim-6fa34caabcd1e9943dc5"],"id":"F6","paraphrase":"An X poster asks how the AREG hypothesis discussed in connection with COSINR could be tested in humans and distinguished from ordinary metastatic progression.","source_channel":"x_thread","source_date":"2025-10-22","title":"Human validation, causal discrimination and real-world importance remain contested"}]},"publication":{"approved_at":"2026-10-30T22:21:39Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-30T23:41:00Z","summary":"Corrected to match the delivered report: the sample findings; the report description."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":28},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","118 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion; repeated posts and reposts are not independent clinical opinions.","Some discussion passages and treatment-development suggestions were not fully assessed, and unnamed references or alternative transcriptions may be missing. Absence of a view here does not establish that no such view exists or that every proposed approach has been characterized.","A complete protocol and the complete main clinical-results publication are not available. Presentation summaries and participant recalculations should not substitute for a full endpoint-level assessment.","The registry condition labels describe small cell lung cancer, while the trial title, methods statement and commentary specify stage IV NSCLC. The report follows the latter clinical setting.","Clinical associations involving AREG or YTHDF2 do not establish causation, predictive utility, a sequencing rule or benefit from a targeted intervention.","Some numerical presentation summaries omit denominators, timepoints or group assignments; values from different presentations are not interchangeable.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","A speaker's favorable appraisal accompanies a post sharing COSINR results. Another speaker's AREG explanations concern the group's own research, including COSINR analyses. These should not be read as independent external reception.","A speaker's involvement is described by the source as working for The University, the trial's sponsor; this description is not independent verification of employment or a reason to weight the view as external consensus.","Surgical, bladder-RT and other-trial examples are used only where they qualify the connected treatment or evidence question; they are not COSINR treatment arms or outcomes. The pulmonary-vessel-ligation comparison is a reported study observation posted in 2019 about lung-cancer resection.","Concerns about patient fear, specialty bias and media effects are attributed opinions or anticipated risks, not independently measured findings."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":1,"registry":1,"regulatory":0,"x_thread":21,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":21,"context":1,"methods":1},"count":23,"evidence_window":{"end":"2025-11-28","start":"2018-06-14"},"retrieval_snapshot":"2026-10-30T16:02:39.879952Z","timeline":[{"count":1,"week":"2018-W24"},{"count":1,"week":"2020-W02"},{"count":1,"week":"2020-W03"},{"count":1,"week":"2020-W20"},{"count":1,"week":"2020-W21"},{"count":1,"week":"2020-W44"},{"count":1,"week":"2021-W06"},{"count":1,"week":"2021-W14"},{"count":1,"week":"2021-W15"},{"count":1,"week":"2021-W36"},{"count":1,"week":"2022-W22"},{"count":2,"week":"2022-W48"},{"count":1,"week":"2022-W49"},{"count":1,"week":"2023-W37"},{"count":1,"week":"2024-W19"},{"count":1,"week":"2024-W35"},{"count":2,"week":"2025-W20"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2025-W46"},{"count":2,"week":"2025-W47"},{"count":2,"week":"2025-W48"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT03223155:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03223155:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:41196643","quote_policy":"short_quote_link_out"},{"id":"openfda:f570b9c4-6846-4de2-abfa-4d0a4ae4e394:20260812","quote_policy":"short_quote_link_out"},{"id":"openfda:2265ef30-253e-11df-8a39-0800200c9a66:20260820","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1007067870470103041:0fd0d212-c06e-4b33-b433-ffa105daf444","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1216335283597250562:fe29c7f6-3389-4855-9afd-235d6ce31344","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1262071397527977989:8d10b916-42aa-4365-bb8e-fd5152173b70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1321062921770831874:2411b6a1-5609-4ac4-83c8-7979941c9d29","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1360950485361057792:105698f5-b539-4984-a056-3c5de7dca9a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1380988944305823745:f79d2214-99e1-4867-a0a8-28aaacd5cbc1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1382801944914317313:1585eaa5-99a5-4f9c-aa33-182bfce5eba7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1435210489529786373:36233e90-e6c4-4b55-9a72-e5d3bfcaf51c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1449043361113968646:38ecceb4-0192-46f4-affe-3d78a57c8af9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1532720305948467200:6708bc69-4c39-4ee1-b869-a9ddc00b3ed1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1598051469177094161:79b338c8-bb30-42bb-b585-d3e34eb47bd8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1598392011022811137:a0576b2e-8db2-4aa0-b46d-8ddc9289dc36","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1599847477766721541:b9240e24-f315-4c60-afc7-f5bb3dd16d27","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1669381543830093835:4ba3080d-64ae-4c25-bfdd-072513483aea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701541934043668657:05aa6f09-2182-4621-9e1f-400dbba6cb2d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701566055850885542:f44c3dbf-41c8-47dd-ae63-31704b27d553","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1758536728715862512:c51501b6-e7b6-4728-88b9-bce5463bf26d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1787506682437771624:0b49d3fb-ba76-4e4e-817c-6accc85fe733","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1787639772447404082:8e30c25a-499d-427d-81b9-ff94c2ce9417","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1922691282381553836:cec09dc6-575b-4730-916a-489032cf2a1d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1922985679857795542:93cc6976-7c1c-463b-98bd-f2436fd60237","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981026566466416703:a2766abe-6484-4e75-bf75-33ce386b21ca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986495707302240407:5770468d-2c05-4adb-9113-20ec8c5f6c2b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991592893195383271:0b8f74bb-5d26-4d1c-be97-86cacfb3cf8d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1992650411874894288:1115e5a1-e3f9-40f3-9950-d3a61894c479","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1992652882353570204:24cddeb6-b3f1-43b5-9043-b7d97c846754","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1994096762164764792:d2e63575-e408-48b2-928a-27380d655033","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:963520841978908672:46c268c4-79dc-47d3-a636-7bd976c2b897","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":28,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":28},"count":28,"evidence_window":{"end":"2025-11-28","start":"2018-02-13"},"retrieval_snapshot":"2026-10-30T16:02:39.879952Z","timeline":[{"count":1,"week":"2018-W07"},{"count":1,"week":"2018-W24"},{"count":1,"week":"2020-W02"},{"count":1,"week":"2020-W03"},{"count":1,"week":"2020-W20"},{"count":1,"week":"2020-W21"},{"count":1,"week":"2020-W44"},{"count":1,"week":"2021-W06"},{"count":1,"week":"2021-W14"},{"count":1,"week":"2021-W15"},{"count":1,"week":"2021-W36"},{"count":1,"week":"2021-W41"},{"count":1,"week":"2022-W22"},{"count":2,"week":"2022-W48"},{"count":1,"week":"2022-W49"},{"count":1,"week":"2023-W24"},{"count":2,"week":"2023-W37"},{"count":1,"week":"2024-W07"},{"count":2,"week":"2024-W19"},{"count":1,"week":"2024-W25"},{"count":1,"week":"2024-W35"},{"count":2,"week":"2025-W20"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2025-W46"},{"count":3,"week":"2025-W47"},{"count":2,"week":"2025-W48"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Opdivo"],"label":"nivolumab","slug":"nivolumab"},{"brand_names":["Yervoy"],"label":"ipilimumab","slug":"ipilimumab"}],"indications":[{"reason":"Unmapped registry condition: Stage IV Small Cell Lung Cancer","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"COSINR","aliases":["COSINR","Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer","A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)"],"brief_title":"Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Stage IV Small Cell Lung Cancer"],"display_condition":"stage IV non-small cell lung cancer","display_interventions":[["nivolumab","ipilimumab","stereotactic body radiotherapy"]],"enrollment":{"count":78,"type":"ACTUAL"},"interventions":[{"name":"Nivolumab","synonyms":["Opdivo"],"type":"DRUG"},{"name":"Ipilimumab","synonyms":["Yervoy"],"type":"DRUG"},{"name":"Stereotactic body radiation therapy","synonyms":["SBRT"],"type":"RADIATION"}],"nct_id":"NCT03223155","official_title":"A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_endpoints":[{"description":"To determine the recommended SBRT dose to various metastatic locations in patients with stage IV NSCLC when delivered prior to or concurrently with nivolumab and ipilimumab.","measure":"Number of serious adverse events","timeFrame":"Up to 4 years"}],"registered_date":{"date":"2017-07-21","type":"ACTUAL"},"registry_last_updated":"2026-03-04","registry_url":"https://clinicaltrials.gov/study/NCT03223155","short_name":"COSINR","short_name_basis":"registry_acronym","sponsor":"University of Chicago","start_date":{"date":"2017-09-07","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase1","study_ids":[{"id":"IRB17-0547","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}